Some people inject themselves three or more times a day, sometimes for 50 or 60 years, tempting them to stop the grueling routine, and interrupting treatment can be dangerous.
At ADA 2015, Medtronic announced FDA Clearance of MiniMed Connect, a keychain device that sends pump/CGM data via Bluetooth to a smartphone app and enables remote monitoring for the caregiver. Launch is slated for this fall for MiniMed 530G and Revel users; it will be $199.
Lilly just announced that the FDA has approved its Humalog 200 units/mL KwikPen (insulin lispro) for type 1 and type 2 diabetes, making it the first concentrated mealtime insulin analog to reach the US market. The pen has already been launched in Europe following its approval there last October. No pricing information for the KwikPen […]
Timesulin, a pen cap to help patients remember how long it’s been since their last dose of insulin, is now available in the US after raising an impressive $36,189 from a crowdfunding campaign. This is welcome news for patients on injections and comes after Timesulin’s popularity in 40 other countries.
Lilly just announced that the FDA has approved its Humalog 200 units/mL KwikPen (insulin lispro) for type 1 and type 2 diabetes, making it the first concentrated mealtime insulin analog to reach the US market.
200 million people on this planet worry about the same invisible villain: their blood glucose. High, low, just right? For many of these diabetics, it’s a medical version of Goldilocks that entails four or more blood-test finger pricks a day and a jab in the thigh with a needle full of insulin at mealtimes.
If a glucose meter could make cappuccino, I’d be all over that. That’s what I expected with Abbott Diabetes Care’s newest meter, the FreeStyle Precision Neo, launched here in the States earlier this Spring. But sadly, the meter doesn’t deliver on the promise of delivering my metaphoric cappuccino. It hardly even brews drip coffee, if […]
The number of blood glucose meters on the market today is staggering, and one of the most frequently asked questions in diabetes forums is “What meter do you use?” So, how do you choose?
It’s been 16 months since Dan and Judy Houdeshell lost their son, Kevin, and they are trying to accept that they may never know exactly what happened. Kevin, who was on insulin therapy, was found dead in his home in Sheffield Lake, Ohio on January 8th, 2014. He had been without insulin for nine days […]
In the coming months, we’ll see the Roche Accu-Chek Connect system hit the market here in the States — giving us the first mobile app approved by the FDA that actually offers insulin dosing recommendations, via a built-in bolus calculator.
Individuals with Type 2 Diabetes have difficulty regulating their glucose — or blood sugar — levels, particularly after meals. Now, University of Missouri researchers have found that Type 2 diabetics can eat more protein at breakfast to help reduce glucose spikes at both breakfast and lunch.
Living with diabetes means tracking your meals and insulin level. The new One Drop app for iOS (an Android version is planned) aims to not only make that monitoring easier, but also use the logged information to help the larger diabetic community.
I can’t wait to get my next A1C test done (who says that?! but it’s true). I am now two-plus months into my use of new inhaled insulin Afrezza, and frankly I’m blown away by how well it performs.
Google recently received a patent for its glucose-sensing contact lens, providing the first major update we’ve heard on this project since last July. The patent does not necessarily reflect Google’s latest or final design of the glucose-sensing lens, but it does indicate continued work and interest in the project.
Ever have an issue forgetting your insulin at home, at school or in the office? Or do you worry that freezing or sweltering weather might kill your insulin?
The new device, available in Australia, Denmark, and the U.K., is small, about the size of a MP3 player. The system is the first in the world to both automatically suspend insulin delivery when sensor glucose levels are predicted to approach a low limit and resume insulin delivery once sensor glucose levels recover.
New basal insulin Toujeo (insulin glargine U300) has now launched in the US, around a month after its FDA approval. In what we think is fantastic news, Toujeo will be priced around the same as Lantus (insulin glargine U100) per unit.
I have been using Afrezza, the new inhaled insulin developed by MannKind and marketed by Sanofi, for the last three and a half weeks. So far it’s… mysterious and exciting. Mysterious because the dosing seems ridiculously imprecise compared to the micro-unit counts I’m used to with an insulin pump.
According to a T1D Exchange article, researchers presented positive results in clinical trials of a new glucagon nasal powder at the Advanced Technologies & Treatments Diabetes conference in Paris, France.
If you have type 2 diabetes and find yourself struggling to stick to your daily medication regiment, there may be a new long-term drug delivery system hitting the market.